{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placenta+Stem+Cells&page=2", "query": { "intervention": "Placenta Stem Cells", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placenta+Stem+Cells&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T12:03:48.448Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06841068", "title": "Intrathecal Amniotic Fluid Stem Cells for Progressive Multiple Sclerosis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Sclerosis, Progressive" ], "interventions": [ { "name": "Amniotic fluid or placental CD117 stem cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 0, "start_date": "2026-02", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06841068" }, { "nct_id": "NCT07686094", "title": "Placental Cells for Diabetic Foot Ulcers", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetic Foot Ulcer" ], "interventions": [ { "name": "Placenta Stem Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2026-10", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07686094" }, { "nct_id": "NCT03113786", "title": "CLARIX™ 100 & CLARIX CORD 1K for Discectomy Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Protruded Disk" ], "interventions": [ { "name": "CLARIX™100", "type": "OTHER" }, { "name": "CLARIX CORD 1K", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Amniox Medical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 32, "start_date": "2011-11-02", "completion_date": "2020-04-21", "has_results": false, "last_update_posted_date": "2020-07-15", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 1, "location_summary": "Bensalem, Pennsylvania", "locations": [ { "city": "Bensalem", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113786" }, { "nct_id": "NCT05207722", "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic HER2 Positive Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "CYNK-101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Recombinant Human Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2022-04-14", "completion_date": "2024-02-15", "has_results": false, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 3, "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05207722" }, { "nct_id": "NCT04176120", "title": "Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Foot Infection", "Non-healing Wound", "Non-healing Diabetic Foot Ulcer" ], "interventions": [ { "name": "TTAX01", "type": "BIOLOGICAL" }, { "name": "Standard Care", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "BioTissue Holdings, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2020-07-01", "completion_date": "2024-06-12", "has_results": false, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 16, "location_summary": "San Francisco, California • Sylmar, California • Miami, Florida + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "North Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04176120" }, { "nct_id": "NCT05387278", "title": "Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19 Acute Respiratory Distress Syndrome", "Respiratory Distress Syndrome" ], "interventions": [ { "name": "EV-Pure™ and WJ-Pure™", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vitti Labs, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2025-03-20", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 1, "location_summary": "Liberty, Missouri", "locations": [ { "city": "Liberty", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05387278" }, { "nct_id": "NCT02434965", "title": "Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Hypoxic-ischemic Encephalopathy" ], "interventions": [ { "name": "HPDSC", "type": "DRUG" }, { "name": "Cord blood", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Minute", "maximum_age": "6 Hours", "sex": "ALL", "summary": "1 Minute to 6 Hours" }, "enrollment_count": 0, "start_date": "2019-12", "completion_date": "2022-01", "has_results": false, "last_update_posted_date": "2021-02-23", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 1, "location_summary": "Valhalla, New York", "locations": [ { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02434965" }, { "nct_id": "NCT02395029", "title": "Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peyronie's Disease" ], "interventions": [ { "name": "Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Melissa Marchand", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 5, "start_date": "2013-08", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2015-03-20", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 1, "location_summary": "Coral Springs, Florida", "locations": [ { "city": "Coral Springs", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02395029" }, { "nct_id": "NCT01769755", "title": "A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Crohns Disease" ], "interventions": [ { "name": "PDA001", "type": "BIOLOGICAL" }, { "name": "Vehicle Controlled Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2013-03", "completion_date": "2014-11", "has_results": false, "last_update_posted_date": "2018-03-01", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 12, "location_summary": "Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01769755" }, { "nct_id": "NCT04309084", "title": "Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Neoplasm, Plasma Cell", "Neoplasms by Histologic Type", "Neoplasms", "Hemostatic Disorder", "Vascular Diseases", "Cardiovascular Diseases", "Paraproteinemias", "Blood Protein Disorders", "Hematologic Diseases", "Hemorrhagic Disorders", "Lymphoproliferative Disorders", "Immunoproliferative Disorders", "Immune System Diseases", "Antineoplastic Agents", "Analgesics, Non-Narcotic", "Analgesics", "Sensory System Agents", "Peripheral Nervous System Agents", "Physiological Effects of Drugs" ], "interventions": [ { "name": "CYNK-001", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 29, "start_date": "2020-05-12", "completion_date": "2023-04-30", "has_results": false, "last_update_posted_date": "2023-02-16", "last_synced_at": "2026-09-28T12:03:48.448Z", "location_count": 4, "location_summary": "Denver, Colorado • St Louis, Missouri • Buffalo, New York + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04309084" } ] }